Journal of Infection and Chemotherapy最新文献_第3页

Knowledge, perception, and behaviours related to antibiotic use and antimicrobial resistance in community-dwelling individuals in Hong Kong.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-11 DOI: 10.1016/j.jiac.2024.12.012

Sze Lon Chloe Chui, Siu-Wai Lai, Pei-Yu Huang, Chi Ching Cherrie Pang, Chung Ki Anna Tsui, Hein Min Tun, Sinn Kay Olivia Chan, Peng Wu

{"title":"Knowledge, perception, and behaviours related to antibiotic use and antimicrobial resistance in community-dwelling individuals in Hong Kong.","authors":"Sze Lon Chloe Chui, Siu-Wai Lai, Pei-Yu Huang, Chi Ching Cherrie Pang, Chung Ki Anna Tsui, Hein Min Tun, Sinn Kay Olivia Chan, Peng Wu","doi":"10.1016/j.jiac.2024.12.012","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.012","url":null,"abstract":"Background: Understanding public knowledge and behaviours related to antibiotics and antimicrobial resistance (AMR) may inform interventions to reduce inappropriate antibiotics use.Methods: We conducted a questionnaire survey in community-dwelling adults in Hong Kong from 2020 to 2022 to examine knowledge, risk perception on AMR and antibiotics, and behavioural patterns in antibiotic use. Information on demographics, socioeconomic status and general health was examined in relation to the knowledge score, antibiotic use behaviours and preference for antibiotic-free food products in regression models.Results: Of the 1147 participants, the median knowledge score on AMR and antibiotics was 13 (interquartile range (IQR): 9-17 out of 24). Females (knowledge coefficient: -0.95; 95% confidence interval (CI): -1.65, -0.26) and those aged ≥65 years (-1.91; -2.85, -0.98) had a relatively lower score. Over 94% of antibiotic users reported strict adherence to prescriptions, while most non-compliant users kept unused antibiotics for future use (45/66, 68.2%). Presence of chronic diseases was associated with antibiotic use in the past year (odds ratio (OR): 1.65; 95% CI: 1.20, 2.29). A higher socioeconomic status or knowledge score predicted a better awareness of and preference for antibiotic-free food and stronger belief in AMR-related threats while older age was associated with lower awareness of antibiotic-free food and perceived risk of AMR.Conclusions: The lack of AMR-related knowledge and potentially higher antibiotics exposure, particularly in older, less educated, socioeconomically underprivileged individuals, highlighted the need for improving targeted education and risk communication on AMR in the public.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in Syphilis Treatments and the Impact of Intramuscular Injectable Benzathine Penicillin G in Japan: A Descriptive Study Using Administrative Claims Data from April 2016 to September 2023.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-11 DOI: 10.1016/j.jiac.2024.12.015

Tomokazu Shoji, Manabu Akazawa, Osamu Inoue, Takaaki Suzuki

{"title":"Trends in Syphilis Treatments and the Impact of Intramuscular Injectable Benzathine Penicillin G in Japan: A Descriptive Study Using Administrative Claims Data from April 2016 to September 2023.","authors":"Tomokazu Shoji, Manabu Akazawa, Osamu Inoue, Takaaki Suzuki","doi":"10.1016/j.jiac.2024.12.015","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.015","url":null,"abstract":"Introduction: The incidence of syphilis is increasing in Japan. A new treatment, penicillin intramuscular injection, was launched in January 2022. This study aimed to determine syphilis treatments in Japan and investigate the impact of the new intramuscular penicillin formulation.Materials and methods: Data from the Japanese Administrative Claims Database from January 2016 to September 2023 were used to identify patients diagnosed with syphilis, and the types and annual trends of antimicrobials prescribed were investigated. Furthermore, the characteristics of patients prescribed an intramuscular injection of benzathine penicillin G were compared with those of patients who were not.Results: Overall, 7867 patients were included in the analysis ( 81%, male; 5.4% positive for human immunodeficiency virus). Seventy-five percent of patients were diagnosed with syphilis in facilities with 0-19 beds. Annual trends showed oral amoxicillin as the most prescribed drug to 80% of patients throughout the study period. In 2023, 10.6% of patients received a prescription for an intramuscular penicillin formulation. Compared with those who did not receive this treatment, those who received it tended to have fewer clinic visits over 1 month (p = 0.0256).Conclusions: Oral amoxicillin is the primary treatment for syphilis in Japan; however, the number of patients receiving intramuscular injection of benzathine penicillin G is increasing. Prescribed mainly by clinics, an intramuscular injection of benzathine penicillin G may contribute to a decreased number of office visits.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molnupiravir for high-risk adults with COVID-19: target trial emulation in a Japanese cohort.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-11 DOI: 10.1016/j.jiac.2024.12.016

Yuya Kimura, Hiroki Matsui, Sachiko Ono, So Sato, Hideo Yasunaga

{"title":"Molnupiravir for high-risk adults with COVID-19: target trial emulation in a Japanese cohort.","authors":"Yuya Kimura, Hiroki Matsui, Sachiko Ono, So Sato, Hideo Yasunaga","doi":"10.1016/j.jiac.2024.12.016","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.016","url":null,"abstract":"Background: Evidence on the effectiveness of molnupiravir for high-risk adults in a highly vaccinated Asian population is sparse. In this study, we aimed to estimate the association between molnupiravir use and hospital admission or death in high-risk adults with COVID-19 during the Omicron era.Methods: This retrospective cohort study included high-risk patients diagnosed with COVID-19 in Shimonoseki City between September 16, 2022, and May 8, 2023. The outcome was a composite of hospital admission or death within 28 days. Participants were categorized into two groups: those who used molnupiravir within 5 days of diagnosis and those who did not. The outcomes were compared using a Cox proportional hazards model. Treatment weighting was used to balance patient backgrounds between the groups, and the clone method with inverse probability of censoring weighting was used to adjust for informative censoring.Results: We analyzed 330 patients (190 females, 57.6%) with a mean age of 68.6 years. The proportion of fully vaccinated and boosted patients was 82.9% (155/187) in the molnupiravir group and 90.2% (129/143) in the control group. The overall 28-day incidence of all-cause hospitalization and mortality was 5.2% (17/330), with 3.2% (6/187) in the molnupiravir group and 7.7% (11/143) in the control group. Molnupiravir was associated with a decrease in hospital admissions or death within 28 days (weighted hazard ratio, 0.35 [95% confidence intervals, 0.13 to 0.90]).Conclusions: Molnupiravir was linked to fewer hospitalizations or deaths within 28 days compared to no treatment in highly vaccinated high-risk patients with COVID-19 in Japan.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical efficacy and safety assessment of tedizolid using therapeutic drug monitoring.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-10 DOI: 10.1016/j.jiac.2024.12.011

Yuichi Shibata, Arufumi Shiota, Nobuaki Mori, Nobuhiro Asai, Mao Hagihara, Hiroshige Mikamo

{"title":"Clinical efficacy and safety assessment of tedizolid using therapeutic drug monitoring.","authors":"Yuichi Shibata, Arufumi Shiota, Nobuaki Mori, Nobuhiro Asai, Mao Hagihara, Hiroshige Mikamo","doi":"10.1016/j.jiac.2024.12.011","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.011","url":null,"abstract":"Thrombocytopenia derived from tedizolid (TZD) has been reported but less frequently than that from linezolid. Only a few reports have investigated the relationship between the efficacy and safety of TZD administration. This study aimed to measure TZD concentration and investigate the relationship between efficacy and safety. The study was conducted at the Aichi Medical University Hospital. All patients administered TZD were included; the serum trough concentration (Cmin) of TZD was measured using LM1010 high-performance liquid chromatography. Efficacy was assessed as clinical and microbiological efficacy. Clinical efficacy was defined as no recurrence and no need for additional treatment until 2 weeks after the end of TZD therapy. Microbiological efficacy was defined as the absence of bacteria during and after TZD therapy. Safety was assessed using thrombocytopenia. Thrombocytopenia was defined as a decrease in platelet count of ≥25% compared with baseline levels and a minimum count of <10 × 104/μL. Seventeen patients were included. The Cmin in 16 patients was <0.5 μg/mL; one patient had a Cmin of 1.01 μg/mL complicated by hepatic cirrhosis. Clinical and microbiological efficacy was found in >80% of the patients. Thrombocytopenia occurred in 14.3% (2/14) of the patients. The Cmin in two patients with thrombocytopenia were 0.14 and 0.28 μg/mL, respectively. The serum concentration of TZD might increase in patients with hepatic cirrhosis; therapeutic drug monitoring may be required. Thrombocytopenia due to TZD could occur regardless of its serum concentration, necessitating monitoring for platelet count.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in endemic of respiratory syncytial virus infection during COVID-19 pandemic and difficulty in obtaining optimal timing of palivizumab prophylaxis.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-10 DOI: 10.1016/j.jiac.2024.12.014

Keisuke Taku, Shun Ichikawa, Masato Ogawa, Takayuki Kokubo, Toshihiko Manabe, Kenichi Takano, Saori Murakawa, Hikaru Takahashi, Jun Hirakawa, Yoshihiro Sakemi, Miwa Yoshino, Ryoko Nakamura, Jyunko Yamamoto, Takayuki Hoshina

{"title":"Trends in endemic of respiratory syncytial virus infection during COVID-19 pandemic and difficulty in obtaining optimal timing of palivizumab prophylaxis.","authors":"Keisuke Taku, Shun Ichikawa, Masato Ogawa, Takayuki Kokubo, Toshihiko Manabe, Kenichi Takano, Saori Murakawa, Hikaru Takahashi, Jun Hirakawa, Yoshihiro Sakemi, Miwa Yoshino, Ryoko Nakamura, Jyunko Yamamoto, Takayuki Hoshina","doi":"10.1016/j.jiac.2024.12.014","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.014","url":null,"abstract":"Objective: The coronavirus disease (COVID-19) pandemic has affected the epidemiology of respiratory syncytial virus (RSV) infection. This study assessed whether or not palivizumab prophylaxis was appropriate during the COVID-19 pandemic.Methods: This prospective study included children <24 months old who were hospitalized for RSV infection between April 2019 and March 2023. We compared the clinical characteristics of inpatients with RSV infection, with and without palivizumab prophylaxis.Results: During the investigation period, 2,133 children <24 months old were hospitalized for RSV infection. The hospitalization rate of RSV infection in children receiving palivizumab prophylaxis (0.7%) was significantly lower than that in children without the prophylaxis (3.1%, P <0.001), indicating that the timing of prophylaxis was roughly appropriate in preventing hospitalization for RSV infection. In contrast, palivizumab prophylaxis was performed during the non-endemic period of RSV infection due to changes in RSV infection endemics due to the impact of the COVID-19 pandemic.Conclusion: Palivizumab is useful in preventing hospitalization for RSV infection in children with a high risk of developing severe respiratory tract infections. However, since the RSV infection endemics varies not only during the occurrence of an emerging infectious disease, such as COVID-19, but also from year to year, a system that can quickly recognized the endemics is needed to avoid the inappropriate use of palivizumab. Furthermore, it is also necessary to actively promote maternal RSV vaccination to prevent severe RSV infection in all infants and young children.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal bacteria growth inhibition by a toilet sanitary good for disaster shelter.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-09 DOI: 10.1016/j.jiac.2024.12.010

Shota Murata, Hideki Hayashi, Eiji Ido, Hidetoshi Igari

{"title":"Gastrointestinal bacteria growth inhibition by a toilet sanitary good for disaster shelter.","authors":"Shota Murata, Hideki Hayashi, Eiji Ido, Hidetoshi Igari","doi":"10.1016/j.jiac.2024.12.010","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.010","url":null,"abstract":"Japan has experienced several large earthquakes in the past 30 years. Emergency evacuation shelters become overcrowded immediately after disasters. Deteriorating sanitary conditions in toilets are associated with a higher risk of infectious pathogen transmission. \"Ho!Toilet\" is a toilet sanitary good for emergency evacuation shelters. Its main ingredients are calcium hydroxide, superabsorbent polymer (SAP), and zeolite. SAP absorbs water and solidifies waste for proper disposal. Zeolites are deodorizers. Calcium hydroxide, which inactivates microorganisms, can reduce the risk of infectious diseases in evacuation shelters. In this study, we designed experiments to confirm the antimicrobial effects of the Ho!Toilet. Escherichia coli (E.coli), Vibrio cholerae (V. cholerae), and Clostridioides difficile (C. difficile) were selected as the microorganisms for this study. Two strains of E.coli and two strains of V. cholerae were inactivated, whereas, C. difficile was not. After the Ho!Toilet powder and bacterial solutions were mixed and stirred, the mixture was separated into a gel and a liquid phase. The pH values in the gel and the liquid phase were 12.0 and 9.3, respectively. After centrifugation of these mixtures, the supernatants were cultured with bacteria at pH 10.7. Ho!Toilet inactivates bacteria other than C. difficile in this study. These effects are mainly achieved under alkaline conditions using calcium hydroxide. Considering the additional effects of the ingredients in Ho!Toilet, SAP, and Zeolite, these products would be useful in toilets with poor sanitary conditions, such as evacuation shelters, to prevent the transmission of infectious diseases.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-06 DOI: 10.1016/j.jiac.2024.12.007

Manami Yoshida, Nao Taguchi, Yi Piao, Rikisha Gupta, Jami Peters, Mazin Abdelghany, Mel Chiang, Chen-Yu Wang, Mark Berry, Hiroshi Yotsuyanagi

{"title":"Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan.","authors":"Manami Yoshida, Nao Taguchi, Yi Piao, Rikisha Gupta, Jami Peters, Mazin Abdelghany, Mel Chiang, Chen-Yu Wang, Mark Berry, Hiroshi Yotsuyanagi","doi":"10.1016/j.jiac.2024.12.007","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.007","url":null,"abstract":"Introduction: Remdesivir (RDV) was approved in Japan for the treatment of coronavirus disease 2019 (COVID-19) in May 2020. However, large-scale research describing the characterized use of RDV in the inpatient setting in Japan is limited. This study aimed to describe the treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 treated with RDV.Methods: We used a secondary nationwide administrative claims database of acute care hospitals in Japan. The study period was from October 19, 2020, to September 30, 2022. Patients with COVID-19 treated with RDV during hospitalization were included, and the proportion of patients with death and disease progression were calculated.Results: The analysis included a total of 2,171 immunocompromised patients treated with RDV. The mean (standard deviation) age at index date was 75.1 (13.6) years. The median time to RDV initiation from hospitalization was 1.0 days (Q1-Q3: 1.0-2.0), and the median duration of RDV treatment was 5.0 days (Q1-Q3: 3.0-5.0). At RDV initiation, 53.02% (n=1,151) of patients required non-invasive positive pressure ventilation, nasal high-flow or low-flow oxygen, and 2.26% (n=49) required mechanical ventilation, extracorporeal membrane oxygenation, or intensive care unit admission. Inpatient mortality rate by day 28 was 8.98% (95% confidence interval, 7.81-10.26). By day 28, the rate of disease progression was 9.86% (n=214), and 76.83% (n=1,668) were discharged.Conclusion: This study presents practical information on outcomes and treatment patterns of RDV in immunocompromised inpatients diagnosed with COVID-19.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibody titer trends after SARS-CoV-2 vaccination in patients aged 12 to 25 years with underlying diseases.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-06 DOI: 10.1016/j.jiac.2024.12.008

Taketo Kasai, Masaki Yamada, Takanori Funaki, Chiaki Tao, Shota Myojin, Hiroyuki Aiba, Toshihiro Matsui, Chikara Ogimi, Kozue Miyake, Saki Ueno, Isao Miyairi, Hitoshi Kato, Kensuke Shoji

{"title":"Antibody titer trends after SARS-CoV-2 vaccination in patients aged 12 to 25 years with underlying diseases.","authors":"Taketo Kasai, Masaki Yamada, Takanori Funaki, Chiaki Tao, Shota Myojin, Hiroyuki Aiba, Toshihiro Matsui, Chikara Ogimi, Kozue Miyake, Saki Ueno, Isao Miyairi, Hitoshi Kato, Kensuke Shoji","doi":"10.1016/j.jiac.2024.12.008","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.008","url":null,"abstract":"Background: Whereas declines in antibody titers after SARS-CoV-2 vaccination have been reported, most reports are predominantly from adults. Long-term trends in SARS-CoV-2 antibody titers after the first BNT162b2 vaccination series in children and young adults with underlying diseases remain less studied.Methods: This prospective single-center observational cohort study enrolled patients aged 12-25 years with underlying diseases who received the first BNT162b2 vaccination series. At least three longitudinal antibody titers were evaluated during the first year following vaccination.Results: Among 429 study subjects, 61 patients with at least three subsequent antibody titer measurements were included. The median (interquartile range [IQR]) time intervals from the vaccination to the first, second, and third antibody measurements were 43 (30-56), 126 (110-155), and 224 (207-256) days, and antibody titers declined with median (IQR) values of 2310 (1440-3515), 2010 (1165-3055), and 1410 (904-2195) U/mL, respectively. In 35 immunocompetent patients, the antibody titers decreased consistently in each measurement. In contrast, the antibody titers in immunocompromised patients remained stable between the first and second measurements, but declined by the third. A two-way ANOVA revealed that time was a more significant factor than immunocompromised status for the declines in antibody titers.Conclusions: In patients aged 12-25 years with underlying diseases, antibody titers in immunocompromised patients after SARS-CoV-2 vaccination were lower than in immunocompetent patients in the early post-vaccination period, but they maintained titers similar to the immunocompetent counterpart during the long-term follow-up.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world experience of tixagevimab/cilgavimab prophylaxis in Japanese patients with immunodeficiency.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-05 DOI: 10.1016/j.jiac.2024.12.006

Kento Inoue, Dan Tomomasa, Yu Nakagama, Hiroaki Takeuchi, Yukie Tanaka, Kousuke Tanimoto, Takahiro Kamiya, Takeshi Isoda, Masatoshi Takagi, Keisuke Tanaka, Kota Yoshifuji, Yuki Miwa, Hidenori Ohnishi, Satoshi Okada, Takehiko Mori, Shinsuke Yasuda, Yasutoshi Kido, Tomohiro Morio, Hirokazu Kanegane

{"title":"Real-world experience of tixagevimab/cilgavimab prophylaxis in Japanese patients with immunodeficiency.","authors":"Kento Inoue, Dan Tomomasa, Yu Nakagama, Hiroaki Takeuchi, Yukie Tanaka, Kousuke Tanimoto, Takahiro Kamiya, Takeshi Isoda, Masatoshi Takagi, Keisuke Tanaka, Kota Yoshifuji, Yuki Miwa, Hidenori Ohnishi, Satoshi Okada, Takehiko Mori, Shinsuke Yasuda, Yasutoshi Kido, Tomohiro Morio, Hirokazu Kanegane","doi":"10.1016/j.jiac.2024.12.006","DOIUrl":"10.1016/j.jiac.2024.12.006","url":null,"abstract":"Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe illness and mortality in patients with immunodeficiency. Although vaccination has been recommended, the induction of protective antibodies by immunization, and thus the disease-preventive effect, has proven insufficient in immunodeficient patients, especially in those with predominantly antibody deficiency. A monoclonal antibody combination of tixagevimab and cilgavimab (TIX/CIL) was developed as a pre-exposure prophylaxis (PrEP). In this study, we investigated the post-PrEP increase in antiviral antibody titers and detailed the breakthrough infections that occurred despite PrEP in Japanese immunodeficient patients who had received TIX/CIL.Methods: Blood samples were collected before and after TIX/CIL administration between November 2022 and August 2023. Antibody titers against the S-protein of SARS-CoV-2 were measured to evaluate TIX/CIL-induced protection. Information regarding breakthrough infection, as evidenced by positive antigen and/or PCR tests, was collected.Results: A significant increase in the anti-S antibody titer was observed in all 89 immunodeficient patients who had received TIX/CIL. However, 14 (16 %) patients experienced breakthrough SARS-CoV-2 infections, of which one died of respiratory failure.Conclusion: The shift in the SARS-CoV-2 circulating strain might have reduced the efficacy of TIX/CIL, leading to an increased number of breakthrough infections.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment.

IF 1.9 4区医学

Journal of Infection and Chemotherapy Pub Date : 2024-12-04 DOI: 10.1016/j.jiac.2024.12.005

Pengfei Li, Zhiming Luo, Jianchuan Deng

{"title":"Strategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment.","authors":"Pengfei Li, Zhiming Luo, Jianchuan Deng","doi":"10.1016/j.jiac.2024.12.005","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.005","url":null,"abstract":"Patients with acute myeloid leukemia (AML) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality, including those who were received Venetoclax treatment. Venetoclax, a new oral Bcl-2 inhibitor, targets tumor cells' ability to induce apoptosis. It is the only one which is approved by Food and Drug Administration (FDA) for treating newly diagnosed AML patients who are 75 years of age or older and are ineligible for intensive induction chemotherapy due to existing comorbidities. It has been shown that venetoclax-based regimens raise the risk of invasive fungal diseases (IFD) for AML patients in clinical practice. Because it can lead to prolonged and profound neutropenia in AML patients, with IFD incidence rates ranging from 5.1 % to 32 %, resulting in higher mortality rates. Because of drug-drug interactions between Venetoclax and partial antifungal agents, to choose anti-fungal prophylaxis and to adjust the dosage of agents rationally for AML patients seems crucial to physicians to those who are undergoing venetoclax-based chemotherapy. Therefore, this review aims to summary the mechanism and characteristic of IFD in AML patients and provide practical clinical suggestions and details for the prophylaxis of IFD in AML patients suffering Venetoclax-based treatment.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0